To read the full story, subscribe or sign in.
Nov. 4, 2025
Qyuns Therapeutics Co. Ltd. signed a potential $1.07 billion license deal with Roche Holding AG, granting the latter exclusive rights to QX-031N – a human thymic stromal lymphopoietin and interleukin-33)-targeting bispecific antibody.
BioWorld Asia Deals and M&A Immune Respiratory Bispecific antibody Asia-Pacific Europe IND NMPA